Butyrate induces profound changes in gene expression related to multiple signal pathways in bovine kidney epithelial cells

BMC Genomics

Volumn 7, Issue , 2006, Pages

  Li, Robert W ^a   Li, CongJun ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; OLIGONUCLEOTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CATTLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENERGY METABOLISM; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; KIDNEY EPITHELIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE;

ACETYLATION; ANIMALS; APOPTOSIS; BUTYRATES; CATTLE; CELL CYCLE; CELL LINE; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTONES; KIDNEY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BOS TAURUS;

EID: 33749572256     PISSN: 14712164     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-7-234     Document Type: Article

References (56)

1. Miller SJ: Cellular and physiological effects of short-chain fatty acids. Mini Rev Med Chem 2004, 4(8):839-845.
2. Sharp WM, Johnson RR, Owens FN: Ruminal VFA production with steers fed whole or ground corn grain. J Anim Sci 1982, 55(6):1505-1514.
3. Emenaker NJ, Calaf GM, Cox D, Basson MD, Qureshi N: Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J Nutr 2001, 131(11 Suppl):3041S-6S.
4. Hague A, Paraskeva C: The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Eur J Cancer Prev 1995, 4(5):359-364.
5. Chen JS, Faller DV, Spanjaard RA: Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets 2003, 3(3):219-236.
6. Gassull MA, Cabre E: Nutrition in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2001, 4(6):561-569.
7. Scheppach W, Bartram HP, Richter F: Role of short-chain fatty acids in the prevention of colorectal cancer. Eur J Cancer 1995, 31A(7-8):1077-1080.
8. Johnson IT: Anticarcinogenic effects of diet-related apoptosis in the colorectal mucosa. Food Chem Toxicol 2002, 40(8):1171-1178.
9. Dashwood RH, Myzak MC, Ho E: Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 2006, 27(2):344-349.
10. Saha RN, Pahan K: HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006, 13(4):539-550.
11. Scheppach W, Weiler F: The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 2004, 7(5):563-567.
12. Rupnarain C, Dlamini Z, Naicker S, Bhoola K: Colon cancer: genomics and apoptotic events. Biol Chem 2004, 385(6):449-464.
13. Li CJ, Elsasser TH: Butyrate-induced apoptosis and cell cycle arrest in bovine kidney epithelial cells: involvement of caspase and proteasome pathways. J Anim Sci 2005, 83(1):89-97.
14. Li CJ, Vassilev A, DePamphilis ML: Role for Cdk1 (Cdc2)/cyclin A in preventing the mammalian origin recognition complex's largest subunit (Orc1) from binding to chromatin during mitosis. Mol Cell Biol 2004, 24(13):5875-5886.
15. Kasama T, Miwa Y, Isozaki T, Odai T, Adachi M, Kunkel SL: Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4(3):273-279.
16. Yamamoto I, Matsunaga T, Sakata K, Nakamura Y, Doi S, Hanmyou F: Histone hyperacetylation plays a role in augmentation of IL-4-induced IgE production in LPS-stimulated murine B-lymphocytes by sodium butyrate. J Biochem (Tokyo) 1996, 119(6):1056-1061.
17. Millard AL, Mertes PM, Ittelet D, Villard F, Jeannesson P, Bernard J: Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages. Clin Exp Immunol 2002, 130(2):245-255.
18. Ahmad MS, Krishnan S, Ramakrishna BS, Mathan M, Pulimood AB, Murthy SN: Butyrate and glucose metabolism by colonocytes in experimental colitis in mice. Gut 2000, 46(4):493-499.
19. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K: Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 2004, 23(37):6304-6315.
20. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP: Butyrate inhibits inflammatory responses through NFkap-paB inhibition: implications for Crohn's disease. Gut 2000, 47(3):397-403.
21. Prasad KN, Sinha PK: Effect of sodium butyrate on mammalian cells in culture: a review. In Vitro 1976, 12(2):125-132.
22. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J, Parmentier M, Detheux M: Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003, 278(28):25481-25489.
23. Piekarz R, Bates S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004, 10(19):2289-2298.
24. Bertos NR, Wang AH, Yang XJ: Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol 2001, 79(3):243-252.
25. Ailenberg M, Silverman M: Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy. Biochem Biophys Res Commun 2003, 302(2):181-185.
26. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12(2):220-229.
27. Zeng H, Briske-Anderson M: Prolonged butyrate treatment inhibits the migration and invasion potential of HT1080 tumor cells. J Nutr 2005, 135(2):291-295.
28. Emenaker NJ, Basson MD: Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation. J Surg Res 1998, 76(1):41-46.
29. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A: TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998, 75(2):246-253.
30. Chiba T, Yokosuka O, Fukai K, Kojima H, Tada M, Arai M, Imazeki F, Saisho H: Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology 2004, 66(6):481-491.
31. Baxter RC, Saunders H: Radioimmunossay of insulin-like growth factor-binding protein-6 in human serum and other body fluids. J Endocrinol 1992, 134(1):133-139.
32. Basson MD, Liu YW, Hanly AM, Emenaker NJ, Shenoy SG, Gould Rothberg BE: Identification and comparative analysis of human colonocyte short-chain fatty acid response genes. J Gastrointest Surg 2000, 4(5):501-512.
33. Mariadason JM, Corner GA, Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000, 60(16):4561-4572.
34. Tabuchi Y, Takasaki I, Doi T, Ishii Y, Sakai H, Kondo T: Genetic networks responsive to sodium butyrate in colonic epithelial cells. FEBS Lett 2006, 580(13):3035-3041.
35. Charollais RH, Buquet C, Mester J: Butyrate blocks the accumulation of CDC2 mRNA in late G1 phase but inhibits both the early and late G1 progression in chemically transformed mouse fibroblasts BP-A31. J Cell Physiol 1990, 145(1):46-52.
36. Sun WH, Coleman TR, DePamphilis ML: Cell cycle-dependent regulation of the association between origin recognition proteins and somatic cell chromatin. Embo J 2002, 21(6):1437-1446.
37. Li CJ, Bogan JA, Natale DA, DePamphilis ML: Selective activation of pre-replication complexes in vitro at specific sites in mammalian nuclei. J Cell Sci 2000, 113 (Pt 5):887-898.
38. Li CJ, DePamphilis ML: Mammalian Orc1 protein is selectively released from chromatin and ubiquitinated during the S-to-M transition in the cell division cycle. Mol Cell Biol 2002, 22(1):105-116.
39. Coverley D, Laman H, Laskey RA: Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat Cell Biol 2002, 4(7):523-528.
40. Jiang W, Wells NJ, Hunter T: Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6. Proc Natl Acad Sci U S A 1999, 96(11):6193-6198.
41. Furuno N, den Elzen N, Pines J: Human cyclin A is required for mitosis until mid prophase. J Cell Biol 1999, 147(2):295-306.
42. Gaudier E, Forestier L, Gouyer V, Huet G, Julien R, Hoebler C: Butyrate regulation of glycosylation-related gene expression: evidence for galectin-1 upregulation in human intestinal epithelial goblet cells. Biochem Biophys Res Commun 2004, 325(3):1044-1051.
43. Pool-Zobel BL, Selvaraju V, Sauer J, Kautenburger T, Kiefer J, Richter KK, Soom M, Wolfl S: Butyrate may enhance toxicological defence in primary, adenoma and tumor human colon cells by favourably modulating expression of glutathione S-transferases genes, an approach in nutrigenomics. Carcinogenesis 2005, 26(6):1064-1076.
44. Ranganna K, Yousefipour Z, Yatsu FM, Milton SG, Hayes BE: Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation. Mol Cell Biochem 2003, 254(1-2):21-36.
45. Li RW, Meyer MJ, Van Tassel CP, Sonstegard TS, Conner EE, Van Amburgh ME, Boisclair YR, Capuco AV: Identification of estrogen-responsive genes in the parenchyma and fat pad of the bovine mammary gland by microarray analysis. Physiol Genomics 2006, In press:.
46. Singh-Gasson S, Green RD, Yue Y, Nelson C, Blattner F, Sussman MR, Cerrina F: Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array. Nat Biotechnol 1999, 17(10):974-978.
47. TIGR [http://www.tigr.org]
48. National Center for Biotechnology Information [http://www.ncbi.nlm.nih.gov/geo]
49. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264.
50. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31(4):e15.
51. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19(2):185-193.
52. Bioconductor [http://www.bioconductor.org]
53. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98(9):5116-5121.
54. Department of Statistics-Stanford University [http://www.stat.stanford.edu/ntibs/clickwrap/sam]
55. Larsson O, Wahlestedt C, Timmons JA: Considerations when using the significance analysis of microarrays (SAM) algorithm. BMC Bioinformatics 2005, 6(1):129.
56. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.